| Literature DB >> 35477451 |
Haoran Jiang1, Yu Dong1, Wei Zong1, Xiu-Jie Zhang2, Hui Xu3, Feng Jin4.
Abstract
BACKGROUND: Patients undergoing endocrine therapy for breast cancer often suffer from poor psychosocial adaptation, low compliance with endocrine therapy and poor quality of life. However, the relationship among the three is not completely clear. The aims of this study were to investigate the status of psychosocial adaptation (PSA), medication adherence and quality of life (QOL) in breast cancer women with adjuvant endocrine therapy (AET), and to analyze the influencing factors of QOL and explore the relationship among them.Entities:
Keywords: Adjuvant endocrine therapy; Breast cancer women; Medication adherence; Psychosocial adaptation; Quality of life
Mesh:
Substances:
Year: 2022 PMID: 35477451 PMCID: PMC9044832 DOI: 10.1186/s12905-022-01722-0
Source DB: PubMed Journal: BMC Womens Health ISSN: 1472-6874 Impact factor: 2.742
Data characteristics of research samples and results of univariate analysis (n = 346)
| N (%) | Quality of life | ||
|---|---|---|---|
| Mean ± SD | p | ||
| 0.138 | |||
| < 45 | 88 (25.43) | 99.65 ± 19.99 | |
| 45–54 | 141 (40.75) | 104.41 ± 19.00 | |
| ≥ 55 | 117 (32.82) | 103.46 ± 18.17 | |
| 0.082 | |||
| Low weight | 6 (1.73) | 116.67 ± 22.23 | |
| Normal weight | 157 (45.38) | 101.22 ± 19.34 | |
| Overweight | 154 (44.51) | 104.28 ± 18.67 | |
| Obesity | 29 (8.38) | 101.55 ± 17.77 | |
| 0.421 | |||
| Married | 294 (84.97) | 103.26 ± 19.23 | |
| Unmarried | 9 (2.60) | 93.11 ± 20.31 | |
| Divorced | 27 (7.80) | 101.67 ± 18.43 | |
| widowed | 16 (4.62) | 103.44 ± 15.27 | |
| 0.144 | |||
| Junior high school and below | 96 (27.75) | 100.73 ± 20.16 | |
| High school/technical secondary school | 94 (27.17) | 100.59 ± 20.49 | |
| Junior college | 71 (20.52) | 108.28 ± 16.42 | |
| Bachelor's degree | 78 (22.54) | 103.17 ± 17.76 | |
| Master degree or above | 7 (2.02) | 105.14 ± 13.21 | |
| 0.242 | |||
| Retired | 142 (41.04) | 104.19 ± 17.53 | |
| Did not work | 92 (26.59) | 100.25 ± 20.88 | |
| Temporary worked | 13 (3.76) | 96.46 ± 19.71 | |
| Work as usual | 99 (28.61) | 104.28 ± 19.06 | |
| 0.000** | |||
| Regular exercise | 150 (43.35) | 107.47 ± 17.76 | |
| Irregular exercise | 174 (50.29) | 100.76 ± 18.76 | |
| No exercise | 22 (6.36) | 88.32 ± 20.00 | |
| 0.013* | |||
| Self-pay | 16 (4.62) | 94.00 ± 17.09 | |
| Urban basic medical insurance | 268 (77.46) | 104.28 ± 18.87 | |
| Commercial medical insurance | 5 (1.45) | 83.80 ± 14.02 | |
| Cooperative medical insurance | 50 (14.45) | 99.90 ± 20.09 | |
| Others | 7 (2.02) | 104.43 ± 11.79 | |
| 0.853 | |||
| Tamoxifen | 128 (36.99) | 103.97 ± 17.35 | |
| furlong (Letrozole) | 76 (21.97) | 100.87 ± 19.65 | |
| Exemestane (Arnoxine) | 45 (13.01) | 102.91 ± 18.10 | |
| Torremifene (fareston) | 45 (13.01) | 105.29 ± 18.06 | |
| Others | 52 (15.02) | 101.02 ± 23.45 | |
| Nausea | 0.851 | ||
| Yes | 14 (4.05) | 101.29 ± 20.55 | |
| No | 332 (95.95) | 102.95 ± 18.99 | |
| 0.035* | |||
| Yes | 28 (8.09) | 96.43 ± 19.34 | |
| No | 318 (91.91) | 103.45 ± 18.92 | |
| 0.341 | |||
| Yes | 164 (47.40) | 101.70 ± 19.10 | |
| No | 182 (52.60) | 103.94 ± 18.95 | |
| 0.013* | |||
| Yes | 162 (46.82) | 99.88 ± 20.05 | |
| No | 184 (53.18) | 105.52 ± 17.72 | |
| 0.003** | |||
| Yes | 138 (39.88) | 98.96 ± 19.58 | |
| No | 208 (60.12) | 105.48 ± 8.24 | |
| 0.108 | |||
| Yes | 124 (35.84) | 100.31 ± 20.26 | |
| No | 222 (64.16) | 104.32 ± 18.19 | |
| 0.032* | |||
| Yes | 46 (13.29) | 97.57 ± 18.02 | |
| No | 300 (86.71) | 103.69 ± 19.07 | |
| 0.159 | |||
| Yes | 40 (11.56) | 99.55 ± 16.16 | |
| No | 306 (88.44) | 103.31 ± 19.35 | |
| 0.362 | |||
| Yes | 24 (6.94) | 106.42 ± 17.68 | |
| No | 322 (93.06) | 102.61 ± 19.12 | |
| 0.982 | |||
| Yes | 45 (13.01) | 102.67 ± 19.06 | |
| No | 301 (86.99) | 102.91 ± 19.05 | |
| 0.319 | |||
| Yes | 112 (32.37) | 101.38 ± 19.08 | |
| No | 234 (67.63) | 103.60 ± 19.00 | |
| 0.006** | |||
| 1 species | 109 (31.50) | 107.34 ± 17.50 | |
| 2 species | 87 (25.14) | 103.64 ± 18.43 | |
| 3 species | 62 (17.92) | 102.34 ± 19.95 | |
| 4 species | 45 (13.01) | 101.00 ± 18.23 | |
| 5 species | 20 (5.78) | 88.60 ± 24.71 | |
| ≥ 6 species | 23 (6.65) | 96.39 ± 14.60 | |
| 0.017* | |||
| ≤ 5 | 298 (86.13) | 101.87 ± 19.60 | |
| > 5 | 48 (13.97) | 109.15 ± 13.52 | |
| 0.019* | |||
| < 3 | 175 (50.58) | 100.57 ± 19.80 | |
| 3–6 | 145 (41.91) | 104.17 ± 18.35 | |
| > 6 | 26 (7.51) | 111.27 ± 14.42 | |
| 0.000** | |||
| ≤ 38 | 137 (39.60) | 87.64 ± 16.73 | |
| > 38 | 209 (60.40) | 112.87 ± 12.81 | |
| 0.004** | |||
| Low adherence | 131 (37.86) | 99.15 ± 19.24 | |
| Moderate adherence | 135 (39.02) | 103.33 ± 19.70 | |
| High adherence | 80 (23.12) | 108.23 ± 16.17 | |
*P < 0.05, **P < 0.01
Patients’ quality of life
| Item | N | Minimum | Maximum | Mean | SD |
|---|---|---|---|---|---|
| Physical well-being | 346 | 10 | 28 | 22.61 | 3.72 |
| Social/family well-being | 346 | 1 | 28 | 19.04 | 5.63 |
| Emotional well-being | 346 | 3 | 24 | 18.48 | 4.26 |
| Functional well-being | 346 | 4 | 28 | 19.35 | 5.82 |
| Additional concerns | 346 | 2 | 34 | 23.40 | 5.04 |
| Total QOL score | 346 | 28 | 140 | 102.88 | 19.33 |
Multivariate stepwise regression results of influencing factors of QOL
| Partial regression coefficient B | Standard error | Standardized regression coefficient Beta | t | p | |
|---|---|---|---|---|---|
| Constant term | 40.522 | 3.430 | 11.813 | 0.000 | |
| Psychosocial adaptation | 1.382 | 0.064 | 0.754 | 21.638 | 0.000 |
| Medication adherence | 0.910 | 0.406 | 0.078 | 2.240 | 0.026 |
R2 = 0.593. F = 250.093, p < 0.001
Fig. 1Structural model of standardized medication adherence as mediator
Bootstrap results of mediation effects
| Effect of type | Effect size | Boot | Bootstrap 95%CI | Relative effect ratio | |
|---|---|---|---|---|---|
| SE | The lower limit | The superior limit | |||
| The total effect | 1.405 | 0.064 | 1.280 | 1.530 | – |
| Direct effect | 1.383 | 0.064 | 1.257 | 1.508 | 98.43% |
| Indirect effect | 0.022 | 0.014 | 0.003 | 0.058 | 1.57% |